Statements (55)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:drug
|
gptkbp:bfsLayer |
4
|
gptkbp:bfsParent |
gptkb:Sanofi_Aventis
|
gptkbp:activities |
inhibits von Willebrand factor
|
gptkbp:approves |
gptkb:European_Medicines_Agency
gptkb:U._S._Food_and_Drug_Administration |
gptkbp:class |
gptkb:monoclonal_antibody
|
gptkbp:clinical_trial |
Phase III
used in conjunction with plasma exchange HERCULES trial CAPTIVATE trial used with immunosuppressive therapy |
gptkbp:contraindication |
active bleeding
hypersensitivity to caplacizumab |
gptkbp:dosage_form |
solution for injection
|
gptkbp:duration |
variable based on response
|
gptkbp:education |
advise on signs of allergic reaction
instruct on injection technique importance of follow-up appointments |
gptkbp:effective_date |
2019-02-06
|
gptkbp:excretion |
primarily through the liver
|
gptkbp:formulation |
sterile solution
|
gptkbp:frequency |
daily
|
https://www.w3.org/2000/01/rdf-schema#label |
Cablivi
|
gptkbp:indication |
treatment of adult patients with a TTP
|
gptkbp:ingredients |
caplacizumab
|
gptkbp:interacts_with |
anticoagulants
antiplatelet agents |
gptkbp:is_monitored_by |
signs of bleeding
platelet counts |
gptkbp:is_used_for |
treatment of acquired thrombotic thrombocytopenic purpura
|
gptkbp:manager |
subcutaneous
subcutaneous injection |
gptkbp:manufacturer |
gptkb:Ablynx
|
gptkbp:market |
ongoing
available in pharmacies |
gptkbp:packaging |
pre-filled syringe
|
gptkbp:pharmacokinetics |
binds to von Willebrand factor
half-life of approximately 15 hours |
gptkbp:population |
adults
|
gptkbp:price |
varies by region
|
gptkbp:provides_information_on |
included in treatment protocols for a TTP
|
gptkbp:regulatory_compliance |
approved in multiple countries
|
gptkbp:research_focus |
improving treatment outcomes for a TTP
|
gptkbp:safety_features |
monitor for bleeding complications
|
gptkbp:scholarships |
available for eligible patients
|
gptkbp:side_effect |
fatigue
headache nausea bleeding |
gptkbp:storage |
store in a refrigerator
|
gptkbp:traded_on |
gptkb:Cablivi
|
gptkbp:treatment |
until platelet count recovery
|
gptkbp:type_of_care |
important for treatment efficacy
|
gptkbp:type_of_insurance |
may require prior authorization
|